SMMT — Summit Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1599298 ·
Last close
$14.13
Market Cap
$10.97B
52W High
$29.23
52W Low
$12.55
ADV30
5,616,248
Next earnings
2026-04-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -195,212,000 | -189,424,000 | 647,856,000 | 106,515,000 | 101,924,000 |
| Dec 2025 | 0 | — | -224,875,000 | -219,172,000 | 751,182,000 | 225,266,000 | 92,322,000 |
| Sep 2025 | 0 | — | -234,211,000 | -231,793,000 | 261,729,000 | 238,554,000 | 69,466,000 |
| Jun 2025 | 0 | — | -568,437,000 | -565,708,000 | 324,037,000 | 297,872,000 | 64,598,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-384,053,000
Investing CF
$-334,658,000
Financing CF
$613,653,000
CapEx
$-902,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.60
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,483,583,000
Inventory
—
Receivables
—
ST Investments
$492,216,000
EBIT TTM
$-1,211,835,000
Pretax Income TTM
$-1,206,047,000
Interest Exp TTM
$0
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,094,374,000 | -1,079,586,000 | 751,182,000 | 92,322,000 | — | -322,930,000 |
| Dec 2024 | 0 | -210,977,000 | -221,315,000 | 435,560,000 | 46,812,000 | — | -142,106,000 |
| Dec 2023 | 0 | -88,735,000 | -614,928,000 | 202,949,000 | 125,257,000 | — | -76,760,000 |
| Dec 2022 | 705,000 | -63,621,000 | -78,782,000 | 664,168,000 | 537,514,000 | — | -41,582,000 |
TTM Snapshot
Revenues TTM
$1,529,000
NetIncome TTM
$-118,506,000
OpCashFlow TTM
$0
Assets (Latest)
$435,560,000
Forward EPS
$-1.18
Max Pain — expiry 2026-06-18
max pain strike: $14.00 · spot: $13.88 · call oi: 38,932 · put oi: 12,465
Expected Move to 2026-06-18:
±$0.73
(5.23%) —
implied range
$13.15 –
$14.60
· ATM straddle on $14.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $10.87B | $77.15 | — |
| RDY | DR REDDYS LABORATORIES LTD | $11.10B | $13.33 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.76B | $55.65 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $11.52B | $499.76 | — |
| ELAN | Elanco Animal Health Inc | $12.13B | $24.29 | — |
News headlines (Yahoo Finance, 1h cache)
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering
2026-06-13 15:28 · Yahoo
Summit Therapeutics Halts US$500m Offering After Ivonescimab Trial Results
2026-06-12 16:15 · Yahoo
Stocks Settle Sharply Lower on Escalating Middle East Tensions
2026-06-10 20:38 · Yahoo
Stocks Resume Decline as Chipmakers and AI Companies Fall
2026-06-10 15:21 · Yahoo
Stocks Fall on Weakness in Tech and Trucking Companies
2026-06-10 14:09 · Yahoo
Why Is SMMT Stock Tumbling Today?
2026-06-10 11:19 · Yahoo
Summit Therapeutics Announces Proposed Public Offering of Common Stock
2026-06-09 20:47 · Yahoo
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
2026-06-07 13:30 · Yahoo
Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock
2026-06-07 12:59 · Yahoo
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data
2026-06-05 16:36 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-06-12 14:35:11 | 2026-06-12 | Zanganeh Mahkam | Co-CEO, 10% | P - Purchase | 13.12 | 3810000 | 49987200 |
| 2026-06-12 12:28:50 | 2026-06-12 | Duggan Robert W | Co-CEO, 10% | P - Purchase | 13.12 | 3810000 | 49987200 |